The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Curcumin shows some activity in pancreatic cancer

    Researchers from The University of Texas M. D. Anderson Cancer Center in Houston and Sabinsa Corporation in Piscataway, New Jersey report on early research into the activity of curcumin (diferuloylmethane) in patients with pancreatic cancer.

    First, the details.

    • 25 patients received 8 grams of curcumin by mouth daily until disease progression, with restaging every 2 months.
    • Blood levels for interleukin (IL)-6, IL-8, IL-10, and IL-1 receptor antagonists, and activity of NF-{kappa}B and cyclooxygenase-2 were monitored.
      • Interleukins help the immune system fight cancer.
      • Incorrect regulation of NF-{kappa}B is linked to cancer and improper immune response.
      • The enzyme cyclooxygenase-2 makes prostaglandins that cause inflammation, pain, and fever.

    And, the results.

    • Low blood levels of curcumin were detected as glucuronide and sulfate conjugate forms.
    • 2 patients showed clinical biological activity.
      • One had stable disease for longer than 18 months.
      • Another had brief tumor regression (73%) accompanied by significant increases in interleukins.
    • No toxicity was observed.
    • Curcumin reduced the activity of NF-{kappa}B and cyclooxygenase-2.

    The bottom line?
    The authors concluded, “Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.”

    Sabinsa Corporation manufactures curcumin and other phytonutrients, as well as Ayurvedic herbal extracts. This appears to be an initial attempt to get data that will permit FDA-approved statements for their product.

    In case you forgot, curcumin gives the spice turmeric (Curcuma longa) its yellow color.

    8/27/08 17:11 JR

    Leave a Comment

    You must be logged in to post a comment.